Opus Genetics (IRD): Chief Financial Officer Gagnon Robert E. sold $49,650 worth of shares (14,000 units at $3.55) as part of a pre-agreed trading plan (SEC Form 4)

Historical context for IRD

Across the 29 sessions after earlier IRD headlines, the stock closed higher 12 times and lower 15 times, with a median move of 2.3% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.

Earlier insider filings at IRD

• Oct 27, 2026Chief Executive Officer Magrath George sold $34,384 worth of shares (9,591 units at $3.59) (SEC Form 4)
• Oct 2, 2026Director Foundation Fighting Blindness Retinal Degeneration Fund sold $2,755,981 worth of shares (556,000 units at $4.96) (SEC Form 4)
• Sep 11, 2026Chief Executive Officer Magrath George exercised 392,157 shares at a strike of $1.15 and covered exercise/tax liability with 75,541 shares, increasing direct ownership by 18% to 2,048,485 units (SEC Form 4)
• Sep 8, 2026Chief Financial Officer Gagnon Robert E. sold $127,212 worth of shares (28,000 units at $4.54) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 556,375 units (SEC Form 4) to cover withholding tax
• Sep 8, 2026Director Gallagher Cam exercised 784,314 shares at a strike of $1.15, increasing direct ownership by 39% to 2,800,111 units (SEC Form 4)